Heba Ismail’s Post

View profile for Heba Ismail, graphic

Double Board Certified Physician Scientist and Type 1 Diabetes Researcher.

Talk to me about the use of #transcriptomics in immunology? I’d like to learn more. In this post-hoc analysis from the TN10 trial in #TrialNet, a randomized placebo-controlled trial using #Teplizumab vs. placebo in stage 2 #T1D, the investigators Ana Lledo Delgado Kevan Herold and colleagues aimed to understand the underlying mechanisms of persistence of response in responders to teplizumab. They describe what they call an ‘operational tolerance’ in responders with a pattern of initial increase in transcriptomic signatures of CD8+ T cell activation followed by a decline at 18 months with features of immune regulation and exhaustion. The numbers are small, though the authors validated and confirmed findings in a second sub-cohort as well as compared to data from healthy controls from published data. Now go read it! https://lnkd.in/efKXu6YH

  • diagram

It would be interesting to see Ruxolitinib (see: DOI: 10.1056/NEJMc2022226*) paired with Teplizumab. * https://www.nejm.org/doi/10.1056/NEJMc2022226

To view or add a comment, sign in

Explore topics